A pathogenetic substantiation and efficacy of systemic enzyme therapy in hepatitis C
The authors studied the hepatoprotective effect of Wobenzym on an experimental model of hepatitis (340 white rats) with twostep screening determining the drug's hepatoprotective activity coefficient and examining the biochemical indices of the blood and liver. The clinical part of the study included 57 patients with acute hepatitis С The indices of blood catecholamines, histamine, serotonin, 11 -oxycorticosteroids were detected. An improvement of hormonal balance and a slower development of liver fibrosis in using Wobenzym were found. Administration of the systemic enzyme therapy drug optimized the treatment of the patients: the abdominal and dyspeptic syndromes were stopped rapidly, bilirubin, alkaline phosphatase, cytolytic enzymes normalized, the neurotransmission balance improved. A catamnestic examination 6 months after the therapy revealed an improvement of the biochemical indices. The systemic enzyme therapy drug Wobenzym can be included in a pathogenetic treatment as soon as in the acute period of hepatitis С